Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Acute Kidney Injury

In brief

The goal of this clinical trial is to repurpose cilastatin for preventing acute kidney injury (AKI) in hospitalized patients receiving nephrotoxic medications. The trial will evaluate the efficacy of the re-purposed drug. The main questions it aims to answer are: \- whether cilastatin will prevent nephrotoxic AKI in hospitalized patients. Researchers will compare the drug cilastatin to a placebo (a look-alike substance that contains no drug) to see if drug cilastatin works to prevent AKI in hospitalized patients receiving nephrotoxic medications. Participants will: * Receive drug Cilastatin or a placebo intravenously every 6 hours for up to 24 hours after last exposure to nephrotoxic medication * Have blood test for kidney function every day they are on treatment. * Have a follow-up blood test at 90 days after randomization * Have a telephone survey at 90 days after randomization

Key facts

Study ID: NCT06886464
Run by: Matthew James
People needed: 698
Starts: 2025-07-16
Expected to finish: 2029-12-01
Last updated by the study team: 2025-11-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥ 18 years
Active treatment with an eligible nephrotoxic medication- IV vancomycin, IV aminoglycoside (gentamicin or tobramycin), IV calcineurin inhibitor (cyclosporine or tacrolimus), or IV or intraperitoneal platin-based chemotherapy or ifosfamide; or intraarterial radiographic contrast with two or more high-risk nephrotoxic medication exposures according to the NINJA algorithm.
Able to provide informed consent or have an authorized representative available and willing to give written informed consent after being properly informed of the nature and risks of the Study.

You may not qualify if…

Stage 3 AKI based on Kidney Disease Improving Global Outcomes (KDIGO) SCr or urine output criteria, or receipt of short-term dialysis.
Category G5 CKD (defined as a CKD-EPI eGFR or <15 mL/min/1.73 m2) or being treated with maintenance dialysis or a kidney transplant.
Pregnancy or lactation
Known hypersensitivity to imipenem-cilastatin.
Active or recent treatment (within 48 hours) with imipenem-cilastatin
Active or recent treatment (within 48 hours) with probenecid (medication used for gout prevention that inhibits cilastatin excretion and decreases plasma clearance)
Treatment with another investigational medicinal product or participation in another interventional Study within 30 days
Inability to comply with the requirements of the Study protocol.

Where it is running

University of Calgary — Calgary, Alberta, Canada (enrolling)
University of Alberta — Edmonton, Alberta, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.